Dr Sandra K Burchett, MD | |
300 Longwood Ave, Lo 650, Boston, MA 02115-5724 | |
(617) 355-6832 | |
Not Available |
Full Name | Dr Sandra K Burchett |
---|---|
Gender | Female |
Speciality | Pediatric Medicine |
Experience | 41 Years |
Location | 300 Longwood Ave, Boston, Massachusetts |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1063594455 | NPI | - | NPPES |
3118000 | Medicaid | MA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2080P0208X | Pediatrics - Pediatric Infectious Diseases | 78568 (Massachusetts) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Children's Hospital Pediatric Associates, Inc | 3476541830 | 246 |
News Archive
Diseases that affect tubular structures in the body, such as the gastrointestinal (GI) system, vasculature and airway, present a unique challenge for delivering local treatments.
Shenzhen Beike Biotechnology Co. Ltd., China's leading stem cell research and regenerative medicine company, announced the formation of Beike Holdings Limited a joint venture with Bangkok-based SiriCell Technologies, Inc. Beike Holdings, which is headquartered in Bangkok, Thailand, will focus primarily on the establishment of new international subsidiaries and the development of collaborative hospital partnerships with Southeast Asia's leading healthcare providers.
Nuvelo Inc. today announced that it has been granted fast track designation by the U.S. Food and Drug Administration (FDA) for its lead product candidate, alfimeprase, for the treatment of acute peripheral arterial occlusion (PAO), or "leg attack."
This circumstance is particularly acute regarding states' decisions about setting up health exchanges.
› Verified 3 days ago
Entity Name | Children's Hospital Pediatric Associates, Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1457306664 PECOS PAC ID: 3476541830 Enrollment ID: O20040504000964 |
News Archive
Diseases that affect tubular structures in the body, such as the gastrointestinal (GI) system, vasculature and airway, present a unique challenge for delivering local treatments.
Shenzhen Beike Biotechnology Co. Ltd., China's leading stem cell research and regenerative medicine company, announced the formation of Beike Holdings Limited a joint venture with Bangkok-based SiriCell Technologies, Inc. Beike Holdings, which is headquartered in Bangkok, Thailand, will focus primarily on the establishment of new international subsidiaries and the development of collaborative hospital partnerships with Southeast Asia's leading healthcare providers.
Nuvelo Inc. today announced that it has been granted fast track designation by the U.S. Food and Drug Administration (FDA) for its lead product candidate, alfimeprase, for the treatment of acute peripheral arterial occlusion (PAO), or "leg attack."
This circumstance is particularly acute regarding states' decisions about setting up health exchanges.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Sandra K Burchett, MD 300 Longwood Ave, Lo 650, Boston, MA 02115-5724 Ph: (617) 355-6832 | Dr Sandra K Burchett, MD 300 Longwood Ave, Lo 650, Boston, MA 02115-5724 Ph: (617) 355-6832 |
News Archive
Diseases that affect tubular structures in the body, such as the gastrointestinal (GI) system, vasculature and airway, present a unique challenge for delivering local treatments.
Shenzhen Beike Biotechnology Co. Ltd., China's leading stem cell research and regenerative medicine company, announced the formation of Beike Holdings Limited a joint venture with Bangkok-based SiriCell Technologies, Inc. Beike Holdings, which is headquartered in Bangkok, Thailand, will focus primarily on the establishment of new international subsidiaries and the development of collaborative hospital partnerships with Southeast Asia's leading healthcare providers.
Nuvelo Inc. today announced that it has been granted fast track designation by the U.S. Food and Drug Administration (FDA) for its lead product candidate, alfimeprase, for the treatment of acute peripheral arterial occlusion (PAO), or "leg attack."
This circumstance is particularly acute regarding states' decisions about setting up health exchanges.
› Verified 3 days ago
Puja Banka, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 300 Longwood Ave, Bader 203, Boston, MA 02115 Phone: 617-355-6363 | |
Angela M. Jacques, MD Pediatrics Medicare: Medicare Enrolled Practice Location: Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114 Phone: 617-726-2066 | |
Dr. Elizabeth Susan Taglauer, M.D., PH.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6000 | |
Cailyn Hereen Rood, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6000 | |
Dr. Alon Peltz, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6000 | |
Miki Nishitani, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6000 | |
Vickren Pillay, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6000 |